ImmuCell (ICCC) Projected to Post Earnings on Thursday

ImmuCell (NASDAQ:ICCC) is anticipated to announce its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $5.4010 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:00 AM ET.

ImmuCell Stock Performance

ImmuCell stock opened at $8.45 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.26 and a quick ratio of 1.93. The stock has a fifty day moving average price of $7.09 and a two-hundred day moving average price of $6.39. ImmuCell has a 52-week low of $4.52 and a 52-week high of $9.08. The firm has a market capitalization of $76.47 million, a P/E ratio of -76.81 and a beta of 0.50.

Institutional Investors Weigh In On ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC raised its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 at the end of the most recent reporting period. Institutional investors own 13.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a report on Monday, April 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.